Jochen H Weishaupt
Overview
Explore the profile of Jochen H Weishaupt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
5988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maier A, Kettemann D, Weyen U, Grehl T, Schulte P, Steinbach R, et al.
Sci Rep
. 2025 Mar;
15(1):7360.
PMID: 40025240
In patients with amyotrophic lateral sclerosis (ALS), mechanical insufflation-exsufflation (MI-E) addresses cough deficiency to achieve major therapeutic goals: improving costal muscle and joint function, reducing atelectasis through insufflation, and clearing...
2.
Steinfurth L, Grehl T, Weyen U, Kettemann D, Steinbach R, Rodiger A, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2025 Feb;
:1-12.
PMID: 39985291
Objective: To investigate self-assessment of the amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) using the patient's smartphone and to analyze non-inferiority to clinic assessment. Methods: In an observational study, ALSFRS-R...
3.
Mohwald L, Maier A, Grehl T, Weyen U, Weydt P, GuNTHER R, et al.
Neurol Res Pract
. 2025 Feb;
7(1):6.
PMID: 39910638
Background: In amyotrophic lateral sclerosis (ALS), neurofilament light chain (NfL) was introduced as a prognostic biomarker. More recently, NfL values can be shared on the patient's ALS app. Also, the...
4.
Dash B, Freischmidt A, Helferich A, Ludolph A, Andersen P, Weishaupt J, et al.
Front Cell Neurosci
. 2024 Nov;
18:1457704.
PMID: 39588282
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset disease marked by a progressive degeneration of motor neurons (MNs) present in the spinal cord, brain stem and motor cortex. Death in...
5.
Koch J, Leha A, Bidner H, Cordts I, Dorst J, GuNTHER R, et al.
Lancet Neurol
. 2024 Oct;
23(11):1133-1146.
PMID: 39424560
Background: Fasudil is a small molecule inhibitor of Rho-associated kinase (ROCK) and is approved for the treatment of subarachnoid haemorrhage. In preclinical studies, fasudil has been shown to attenuate neurodegeneration,...
6.
Meyer T, Schumann P, Grehl T, Weyen U, Petri S, Rodiger A, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2024 Sep;
26(1-2):162-171.
PMID: 39268612
Objective: To report the frequency of pathogenic gene variants in a screening program in amyotrophic lateral sclerosis (ALS), and the clinical practice of transition to an expanded access program (EAP)...
7.
Weishaupt J, Kortvelyessy P, Schumann P, Valkadinov I, Weyen U, Hesebeck-Brinckmann J, et al.
Commun Med (Lond)
. 2024 Jul;
4(1):150.
PMID: 39054363
Background: Since the antisense oligonucleotide tofersen has recently become available for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in SOD1, determining the causality of the over 230...
8.
Meyer T, Schumann P, Weydt P, Petri S, Weishaupt J, Weyen U, et al.
Muscle Nerve
. 2024 Jul;
70(3):333-345.
PMID: 39031772
Introduction/aims: In amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations (SOD1-ALS), tofersen received accelerated approval in the United States and is available via expanded access programs (EAP) outside the United...
9.
Opie-Martin S, Iacoangeli A, Topp S, Abel O, Mayl K, Mehta P, et al.
Nat Commun
. 2024 Jul;
15(1):5560.
PMID: 38956107
No abstract available.
10.
Meyer T, Dreger M, Grehl T, Weyen U, Kettemann D, Weydt P, et al.
Eur J Neurol
. 2024 Jun;
31(9):e16379.
PMID: 38859579
Objective: To assess the performance of serum neurofilament light chain (sNfL) in clinical phenotypes of amyotrophic lateral sclerosis (ALS). Methods: In 2949 ALS patients at 16 ALS centers in Germany...